UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported):  September 23, 2008

 

Inovio Biomedical Corporation

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-14888

 

33-0969592

(State or other jurisdiction
 of incorporation)

 

(Commission
 File Number)

 

(I.R.S. Employer
 Identification No.)

 

11494 Sorrento Valley Road, San
Diego, California

 

92121-1318

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:  (858) 597-6006

 

Not Applicable

Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 8.01.  Other Events.

 

Inovio Biomedical Corporation (AMEX:INO), a leader in enabling the development of DNA vaccines using electroporation-based DNA delivery, announced on September 23, 2008 via press release, attached to this report as Exhibit 99.1 and hereby incorporated by reference, that it has received a contract for $933,000 from the Department of Defense (US Army) to continue research and development of DNA-based vaccines delivered via its proprietary electroporation system.

 

Item 9.01.  Financial Statements and Exhibits.

 

(d)           Exhibits

 

99.1         Press Release dated September 23, 2008

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: September 23, 2008

 

 

INOVIO BIOMEDICAL CORPORATION

 

 

 

 

 

By:

/s/ Peter Kies

 

 

Peter Kies, Chief Financial Officer

 

3